Disclaimer: The content provided is for informational purposes only and should not be considered as financial advice. We are not financial advisors, and the information presented is not a substitute for professional consultation. While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or reliability of the information. Any reliance on this information is at your own risk, and we are not liable for any loss or damage arising from its use. It is recommended to consult with a qualified financial professional for specific advice. We reserve the right to modify, update, or remove content without notice.
Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, has a spending problem.
Mydecine is a company that has been in the psychedelic sector since the early 2020s. The Company is developing several prodrug families, starting with a psilocybin-derived smoking cessation treatment in a NIDA-funded Johns Hopkins University study. Mydecine’s primary focus is developing MYCO-006, MDMA-derived short-acting analogs that could be utilized for various indications such as pain and anxiety. If only they could afford it.
Before becoming Mydecine Innovation Group, they began as New Age Farms. They were renamed NewLeaf Brands, before finally renaming again into Mydecine. All three of these companies share a similar picture financially. The assets were finally spun off in 2021, through a company called SpinCo, “SpinCo was incorporated on August 9, 2021 for the purposes of the Transaction, enabling Mydecine to transfer to SpinCo all of the Company’s interests in: (i) 1176392 BC Ltd; (ii) Alternative Distribution Company, LLC; (iii) Drink Fresh Water, LLC; (iv) Tealief Brands, LLC; (v) Relyfe Brands, LLC; (vi) We are Kured, LLC; and (vii) Trellis Holdings Oregon OP, LLC (collectively, the “U.S. Cannabis Subsidiaries”)”. The Journal, Insights: The Corporate and Securities Law Advisor, states: “The most common claims that arise out of spinoffs are for breach of fiduciary duty and fraudulent transfer, although claims alleging unlawful dividends, violations of the securities laws, preferential payments, recharacterization, equitable subordination, and substantive consolidation, among others, also can be asserted.”
Leaders of a company can have an agreement with their own company to provide consulting services that are considered outside the normal scope of the company’s typical operations. They can then bill their own company for such consulting services. This results in more income for them but is paid through the expense Consulting Fees as opposed to salary/management fee.
Please note: I am not claiming any evidence of fraud/fiduciary breach from Mydecine Innovation Group, merely quoting from a corporate law journal.
Let’s get to the real topic at hand, Mydecine’s financials. Below we will be reviewing Mydecine Innovation Groups from 2020-2024. Mydecine has made poor financial decisions from the very start. They had $9,023,124 total expenses for 9 months ending September 30, 2020, revenue being just above $150,000. Out of this $9,023,124, $5,476,923 was spent on share-based payments and Director/management fees, with another $2,600,000 on advertising and Consulting fees. “So what?” you say. They are a new company just getting started and it takes a lot of capital to get up and running, especially in biotech.
Here we will look at their 2020 financials. During that same period a year later, they burned through $14,529,568. Comparing this to a company similar in size at the time, $TRYPF, who only spent half that during the entire year of 2020. $1,800,000 of this was salaries and director/management fees, with another $3,835,207 on Consulting fees, all of this with only $1,500,000 cash on hand at the time these financials were reported.
One would expect them to start reducing their burn rate at this point to be better capitalized for their very costly upcoming clinical trials, right? Wrong. Financials for the 9 months ending September 30, 2022, show differently. While they did decrease total expenses from $14,529,568 to $10,614,356, they still spent $1,810,726 on salaries and director/management fees, with an additional $3,032,041 on Consulting fees. Basically, they reduced the cost in other areas of the business to maintain the same level of compensation, while at the same time reducing the overall expenses.
Surely, they’ve seen the dire financial situation in the market and plan to reduce expenses even more and focus the capital as efficiently as possible? Wrong again, imagine that! Financials for 9 months ending September 30, 2023 show even more egregious spending. Similarly to last year they did indeed cut expenses from $10,614,356 to $7,814,313, they still spend $1,534,307 on salaries and director/management fees, with another $3,630,961 on the ever present Consulting fees. One would think they would consult with an outside financial expert who would advise them to curb their spending and apply what capital they do obtain to the more important of their endeavors. That being said, the management did agree to defer salary, bonuses, and compensation for 2022 and 2023, totaling $3,259.980. This will be “converted into equity”, says Bartch.
The errant spending hasn’t been the only thing to raise eyebrows for this company. Back in 2021 Mydecine CEO Joshua Bartch accusations of unreported insider trades were reported, Bartch claimed “these are NOT sales of stock but private transfers,” to which he “did not receive proceeds’ ‘. Also, on April 20, 2023 Erwin Liem agreed to pay B.C. Securities Commission (BCSC) $40,000 and is barred from the investment market for 20 years. Between July 2014 and April 2017, Liem used the identities “Surya Chandra” and “Li Hong Chang” to obtain and hold securities of Mydecine Innovations Group Inc., now known as New Age Farm, Inc. At the peak of his shareholding, Liem had direction over 24.3 per cent of New Age’s shares (now Mydecine). He held shares through the Chandra and Chang identities, as well as in his own name and through companies he controlled.
The future for Mydecine is uncertain. With the share price dwindling down to the $.01 cent area and a market cap of just $600,000, things don’t look too bright for the once promising company. They announced December 18, 2023, they received a Notice of Allowance from the USPTO for MYCO-005. MYCO-005, a novel compound, that mimics psilocin as an improved version engineered to act therapeutically like psilocin while dramatically reducing highly undesirable side effects from long-term sustained use of psilocybin and almost all-known classical serotonin agonists (LSD, DMT, etc.), specifically addressing valvular fibrosis concerns recognized by leading clinicians and FDA regulators. If they can’t get their spending in check very soon, the $1,104,000 they raised in October 2023 is going to be done as quickly as it came and we may very well end up with one less company in this sector.
*I reached out to pr@mydecineinc.com, investors@mydecineinc.com, hello@mydecineinc.com, and hr@mydecineinc.com for comment, but they didn’t respond. A few of the emails aren’t even active any longer.
**The day the article was posted, the Mydecine team reached out to an email I sent dating back to September 2023.

